EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Bristol Myers Squibb saw a 0.79% gain, closing at $60.28, while the broader market struggled, with the S&P 500 losing 0.91%.

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

William Blair raised their Q3 2026 earnings per share estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the ...

Bristol-Myers Squibb (BMY) is ranked 5th among the best pharma stocks to buy according to hedge funds. The company boasts a ...

This was the stock's second consecutive day of losses.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...